|
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
RECRUITINGPhase 1/2Sponsored by Bristol-Myers Squibb
Actively Recruiting
PhasePhase 1/2
SponsorBristol-Myers Squibb
Started2026-09-15
Est. completion2029-10-30
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations11 sites
View on ClinicalTrials.gov →
NCT07412704
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Eligibility
Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.
Conditions2
ArthritisArthritis, Rheumatoid
Interventions1
Locations11 sites
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1/2
SponsorBristol-Myers Squibb
Started2026-09-15
Est. completion2029-10-30
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations11 sites
View on ClinicalTrials.gov →
NCT07412704